AstraZeneca Pharma share rises 2% on DCGI nod for cancer drug
AstraZeneca Pharma share gained as much as 1.88 per cent to hit a high of Rs 3,480 after the drug maker received import and market permission from the DCGI for osimertinib tablets (Tagrisso) used in treatment of non-small cell lung cancer
BusinessToday.In | March 12, 2021 | Updated 13:19 IST
AstraZeneca Pharma share jumps 2% to Rs 3,480
Share of AstraZeneca Pharma gained nearly 2 per cent in opening deals on Bombay Stock Exchange on Friday after the drug maker received import and market permission from the Drugs Controller General of India (DCGI) for osimertinib tablets (Tagrisso) used in treatment of non-small cell lung cancer. Meanwhile, Sensex was trading 349 points or 0.68 per cent higher at 51,628.